Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.581
Journals
Metabolites
Special Issues
Lipid Expression and Metabolism Aberrations in Skin Diseases
share announcement

Special Issue "Lipid Expression and Metabolism Aberrations in Skin Diseases"

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Lipid Metabolism".

Deadline for manuscript submissions: 30 June 2023 | Viewed by 3858

Special Issue Editors

Dr. Julia Nowowiejska

E-Mail Website
Guest Editor
Department of Dermatology and Venereology, Medical University of Bialystok, 15-089 Bialystok, Poland
Interests: psoriasis; hair and nails disorders; skin cancers
Prof. Dr. Iwona Flisiak

E-Mail Website
Guest Editor
Department of Dermatology and Venereology, Medical University of Bialystok, 15-089 Bialystok, Poland
Interests: psoriasis; bacterial skin infections; pediatric dermatology
Dr. Anna Baran

E-Mail Website
Guest Editor
Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland
Interests: psoriasis; metabolic diseases; pediatric dermatology; atopic dermatitis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We kindly invite you to join us in the new Special Issue of the prestigious journal Metabolites. This time, we are going to focus on lipid expression and metabolism aberrations in different skin diseases.

We warmly invite you to participate in this project and submit papers on different dermatoses that are in your field of expertise and are associated with disturbances in lipid homeostasis. We are going to discuss metabolic complications, their markers, and treatment in relation to skin diseases. Papers regarding psoriasis, lichen planus, vitiligo, hidradenitis suppurativa, alopecia, and others that are associated with lipid aberrations are welcome.

We hope that you accept our invitation and help us to prepare an exceptional Special Issue.

Kind regards,
Dr. Julia Nowowiejska
Prof. Dr. Iwona Flisiak
Dr. Anna Baran
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipids
  • lipid aberrations
  • lipid metabolism
  • skin diseases
  • dermatology
  • psoriasis
  • lichen planus
  • alopecia
  • vitiligo
  • hidradenitis suppurativa

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

get_app
Article
Changes in Lipoprotein Particles in the Blood Serum of Patients with Lichen Planus
by
Liis Ilves
,
Aigar Ottas
,
Liisi Raam
,
Mihkel Zilmer
,
Tanel Traks
,
Viljar Jaks
and
Külli Kingo
Metabolites 2023, 13(1), 91; https://doi.org/10.3390/metabo13010091 - 06 Jan 2023
Cited by 2 | Viewed by 673
Abstract
Lichen planus is a chronic inflammatory mucocutaneous disease that belongs to the group of papulosquamous skin diseases among diseases like psoriasis, a widely studied disease in dermatology. The aim of the study was to identify the changes between the blood sera of lichen [...] Read more.
Lichen planus is a chronic inflammatory mucocutaneous disease that belongs to the group of papulosquamous skin diseases among diseases like psoriasis, a widely studied disease in dermatology. The aim of the study was to identify the changes between the blood sera of lichen planus patients and healthy controls to widen the knowledge about the metabolomic aspect of lichen planus and gain a better understanding about the pathophysiology of the disease. We used high-throughput nuclear magnetic resonance (NMR) spectroscopy to measure the levels of blood serum metabolites, lipoproteins and lipoprotein particles. Dyslipidemia has relatively recently been shown to be one of the comorbidities of lichen planus, but the changes in the components of lipoproteins have not been described yet. We found statistically significant changes in the concentrations of 16 markers regarding lipoproteins, which included the components of intermediate-density lipoproteins, low-density lipoproteins and large low-density lipoproteins. We propose that the detected changes may increase the risk for specific comorbidities (e.g., dyslipidemia) and resulting cardiovascular diseases, as the turnover and hepatic uptake of the altered/modified lipoprotein particles are disturbed. Full article
(This article belongs to the Special Issue Lipid Expression and Metabolism Aberrations in Skin Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

get_app
Review
Lipid Aberrations in Lichen Planus
by
Julia Nowowiejska
,
Anna Baran
and
Iwona Flisiak
Metabolites 2022, 12(11), 1008; https://doi.org/10.3390/metabo12111008 - 22 Oct 2022
Viewed by 1103
Abstract
Lichen planus (LP) is a dermatosis without a fully understood etiopathogenesis, the frequency of which is estimated to be less than 1% among the population. LP may involve the glabrous skin, mucosal membranes, scalp, nails and genital area. Nowadays, there are reports of [...] Read more.
Lichen planus (LP) is a dermatosis without a fully understood etiopathogenesis, the frequency of which is estimated to be less than 1% among the population. LP may involve the glabrous skin, mucosal membranes, scalp, nails and genital area. Nowadays, there are reports of its association with lipid homeostasis aberrations. In this review, we present the contemporary view of this matter. Dyslipidemia, especially hypertriglyceridemia, seems to be an actual problem in this group of patients, and along with abnormal arterial vessel parameters, indicates an increased risk of atherosclerosis in these subjects. Dermatologists should be attentive to this relationship and aware that the patients may develop different metabolic complications. More studies are required to establish clear guidelines on the management of lipid aberrations in lichen planus. Full article
(This article belongs to the Special Issue Lipid Expression and Metabolism Aberrations in Skin Diseases)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

get_app
Systematic Review
Effects of Hypolipidemic Drugs on Psoriasis
by
Mateusz Matwiejuk
,
Hanna Mysliwiec
,
Olivia Jakubowicz-Zalewska
,
Adrian Chabowski
and
Iwona Flisiak
Metabolites 2023, 13(4), 493; https://doi.org/10.3390/metabo13040493 - 29 Mar 2023
Viewed by 659
Abstract
Psoriasis is a chronic, systematic, inflammatory disease in which multiple metabolic and immunologic disturbances lead to lipid abnormalities, impaired glucose tolerance, metabolic syndrome, diabetes mellitus, atherosclerosis, hypertension, ischemic heart disease, and numerous metabolic disorders. In clinical practice, the most commonly used drugs in [...] Read more.
Psoriasis is a chronic, systematic, inflammatory disease in which multiple metabolic and immunologic disturbances lead to lipid abnormalities, impaired glucose tolerance, metabolic syndrome, diabetes mellitus, atherosclerosis, hypertension, ischemic heart disease, and numerous metabolic disorders. In clinical practice, the most commonly used drugs in the treatment of lipid abnormalities are statins and fibrates. Statins are characterized by pleiotropic effects such as antioxidant, anti-inflammatory, anticoagulant, and antiproliferative. They work by reducing the concentrations of low-density lipoprotein (LDL), total cholesterol, and triglycerides and stabilizing atherosclerotic plaque. Fibrates are medications, which help to lower triglycerides, LDL, very low-density lipoprotein (VLDL) levels and increase lower high-density lipoprotein (HDL). In recent years, many new drugs were found to normalize the lipid profile in patients with psoriasis: glitazones (pioglitazone, troglitazone), and glucagon-like peptide-1 (GLP-1) receptor agonists. Pioglitazone improves the lipid profile, including the decrease of triglycerides, fatty acids, and LDL, as well as the increase of HDL. Glucagon-like peptide 1 (GLP-1) analogs decrease modestly low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides. The purpose of this study is to assess the current state of knowledge on the effect of different hypolipidemic treatments on the course of psoriasis. The study includes literature from medical databases PubMed and Google Scholar. We were browsing PubMed and Google Scholar until the beginning of December. The systematic review includes 41 eligible original articles. Full article
(This article belongs to the Special Issue Lipid Expression and Metabolism Aberrations in Skin Diseases)
►▼ Show Figures

Figure 1

get_app
Systematic Review
The Role of Sphingolipids in the Pathogenesis of Psoriasis
by
Mateusz Matwiejuk
,
Hanna Mysliwiec
,
Adrian Chabowski
and
Iwona Flisiak
Metabolites 2022, 12(12), 1171; https://doi.org/10.3390/metabo12121171 - 24 Nov 2022
Cited by 2 | Viewed by 905
Abstract
Psoriasis is a complex, chronic, immunologically mediated disease which involves skin and joints. Psoriasis is commonly connected with numerous other diseases such as liver diseases, metabolic syndrome, impaired glucose tolerance, diabetes mellitus, atherosclerosis, hypertension, and ischemic heart disease. Interestingly, comorbidities of psoriasis are [...] Read more.
Psoriasis is a complex, chronic, immunologically mediated disease which involves skin and joints. Psoriasis is commonly connected with numerous other diseases such as liver diseases, metabolic syndrome, impaired glucose tolerance, diabetes mellitus, atherosclerosis, hypertension, and ischemic heart disease. Interestingly, comorbidities of psoriasis are an attention-grabbing issue. Additionally, it can cause impairment of quality of life and may be associated with depressive disorders. Altered levels of ceramides in psoriatic skin may lead to anti-apoptotic and pro-proliferative states, consequently leading to an over-proliferation of keratinocytes and the development of skin lesions. The pathophysiology of psoriasis and its comorbidities is not fully understood yet. Sphingolipids (including ceramides) and their disturbed metabolism may be the link between psoriasis and its comorbidities. Overall, the goal of this review was to discuss the role of sphingolipid disturbances in psoriasis and its comorbidities. We searched the PubMed database for relevant articles published before the beginning of May 2022. The systematic review included 65 eligible original articles. Full article
(This article belongs to the Special Issue Lipid Expression and Metabolism Aberrations in Skin Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop